Literature DB >> 26846784

Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction.

Megumi Oshima1,2, Yasunori Iwata3,4,5, Kengo Furuichi1,2, Norihiko Sakai1,2, Miho Shimizu1,2, Akinori Hara1,2, Shinji Kitajima1,2, Tadashi Toyama1,2, Yasuyuki Shinozaki1,2, Akihiro Sagara1,2, Eri Umeda1, Shuichi Kaneko2, Satoko Arai6, Toru Miyazaki6, Takashi Wada1,7.   

Abstract

BACKGROUND: Apoptosis inhibitor of macrophage (AIM) expressed on macrophages prolongs inflammation by protecting macrophages from apoptosis. Most circulating AIM co-exists with immunoglobulin M (IgM). AIM's pathophysiological role in relation to IgM remains unclear. Here we evaluated the glomerular expression/deposition of AIM and IgM in the kidney using immunohistochemistry and its associations with clinical manifestations in 43 patients with biopsy-confirmed kidney diseases.
METHODS: Kidney biopsy tissue from all patients was immunostained for AIM and IgM. Staining patterns and percent stained areas within the glomeruli were determined. Cells expressing AIM were identified by co-staining with macrophage and endothelial cell surface markers. Correlations between staining results and clinical parameters were evaluated using univariate and multivariate analyses.
RESULTS: AIM was deposited in various areas, such as mesangial and capillary area. A part of AIM expression was localized to CD68-positive macrophages in the glomerulus. Amount of glomerular expression was positively correlated with urinary protein in patients with severe proteinuria (urinary protein ≥0.5 g/day) and kidney dysfunction [estimated glomerular filtration ratio (eGFR) <60 ml/min/1.73 m2]. Urinary protein was higher in patients exhibiting overlapping glomerular expression of AIM and IgM. Annual eGFR decline rate negatively correlated with AIM-positive area. AIM-positive area and initial serum creatinine were independently associated with decreased kidney function.
CONCLUSION: AIM expression in the kidney was associated with urinary protein and decline in kidney function. Co-expression with IgM appeared to exacerbate AIM's deleterious effects on kidney function. Combined glomerular AIM and IgM expression is a candidate prognostic index for kidney disease.

Entities:  

Keywords:  Apoptosis inhibitor of macrophage (AIM); IgM; Kidney disease

Mesh:

Substances:

Year:  2016        PMID: 26846784     DOI: 10.1007/s10157-016-1240-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  23 in total

1.  IgM nephropathy; time to act.

Authors:  Muhammed Mubarak
Journal:  J Nephropathol       Date:  2014-01-01

2.  Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1).

Authors:  T Wada; H Yokoyama; K Furuichi; K I Kobayashi; K Harada; M Naruto; S B Su; M Akiyama; N Mukaida; K Matsushima
Journal:  FASEB J       Date:  1996-10       Impact factor: 5.191

3.  Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine.

Authors:  Tadashi Uramatsu; Tomoya Nishino; Yoko Obata; Yohei Sato; Akira Furusu; Takehiko Koji; Toru Miyazaki; Shigeru Kohno
Journal:  Biol Pharm Bull       Date:  2013       Impact factor: 2.233

4.  Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice.

Authors:  Yasunori Iwata; Elisabeth A Boström; Julia Menke; Whitney A Rabacal; Laurence Morel; Takashi Wada; Vicki R Kelley
Journal:  J Immunol       Date:  2012-03-30       Impact factor: 5.422

5.  Involvement of extracellular signal-regulated kinase and p38 in human diabetic nephropathy.

Authors:  Norihiko Sakai; Takashi Wada; Kengo Furuichi; Yasunori Iwata; Keiichi Yoshimoto; Kiyoki Kitagawa; Satoshi Kokubo; Motoo Kobayashi; Akinori Hara; Junya Yamahana; Toshiya Okumura; Kazuya Takasawa; Shin-Ichi Takeda; Mitsuhiro Yoshimura; Hiroshi Kida; Hitoshi Yokoyama
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

6.  Mesangial proliferative glomerulonephritis.

Authors:  H K Bhasin; J G Abuelo; R Nayak; A R Esparza
Journal:  Lab Invest       Date:  1978-07       Impact factor: 5.662

7.  IgM contributes to glomerular injury in FSGS.

Authors:  Derek Strassheim; Brandon Renner; Sarah Panzer; Richard Fuquay; Liudmila Kulik; Danica Ljubanović; V Michael Holers; Joshua M Thurman
Journal:  J Am Soc Nephrol       Date:  2013-02-07       Impact factor: 10.121

8.  Obesity-associated autoantibody production requires AIM to retain the immunoglobulin M immune complex on follicular dendritic cells.

Authors:  Satoko Arai; Natsumi Maehara; Yoshihiro Iwamura; Shin-ichiro Honda; Katsuhiko Nakashima; Toshihiro Kai; Masato Ogishi; Kumiko Morita; Jun Kurokawa; Mayumi Mori; Yuji Motoi; Kensuke Miyake; Nobuyuki Matsuhashi; Ken-ichi Yamamura; Osamu Ohara; Akira Shibuya; Edward K Wakeland; Quan-Zhen Li; Toru Miyazaki
Journal:  Cell Rep       Date:  2013-04-04       Impact factor: 9.423

9.  Blockade of CCR2 ameliorates progressive fibrosis in kidney.

Authors:  Kiyoki Kitagawa; Takashi Wada; Kengo Furuichi; Hiroyuki Hashimoto; Yoshiro Ishiwata; Masahide Asano; Motohiro Takeya; William A Kuziel; Kouji Matsushima; Naofumi Mukaida; Hitoshi Yokoyama
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 10.  Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases.

Authors:  Satoko Arai; Toru Miyazaki
Journal:  Semin Immunopathol       Date:  2013-11-27       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.